Navigation Links
Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
Date:6/24/2011

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced additional results from a phase 2 study of an investigational, once-monthly injectable suspension formulation of exenatide which showed substantial improvements in glycemic control, including reductions in A1C and fasting plasma glucose, with modest weight loss. These findings will be presented in a late breaking poster session at the 71st Scientific Sessions of the American Diabetes Association on Sunday, June 26 from 12-2 p.m. PDT.

The 121-patient study assessed the efficacy, safety and tolerability of three different doses (5 mg, 8 mg and 11 mg) of exenatide once monthly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. After 20 weeks of treatment (total of five injections), patients receiving exenatide once monthly experienced average improvements in A1C (a measure of average blood sugar over three months) from baseline of 1.3 percentage points for the 5 mg and 8 mg doses and 1.5 percentage points for the 11 mg dose. In addition, 50 percent of those treated with the 5 mg dose, 57 percent treated with the 8 mg dose and 70 percent treated with the 11 mg dose achieved an A1C of less than 7 percent, the ADA-recommended target for good glucose control. Patients also lost a modest amount of weight (0.9 pounds with the 8 mg dose and 2.4 pounds with the 5 mg and 11 mg doses), although exenatide once monthly is not being studied as a weight-loss product. Fasting plasma glucose was improved with all doses, with reductions of 25 mg/dL with the 5 mg dose, 30 mg/dL with the 8 mg dose and 49 mg/dL with the 11 mg dose. The mean pharmacokinetic p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
2. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
4. Exenatide Once Weekly New Drug Application Review Extended By FDA Due to Weather-Related Closure
5. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
9. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
10. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
11. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... and TORONTO , May 4, ... (OTCQB:GNBT) today announced that it intends to dividend to ... upon completion of a definitive licensing agreement to license ... ( www.smoofi.com ) (OTCQB:SMFI). As announced on ... of intent in respect of the licensing of its ...
(Date:5/4/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) announced ... appointing  Donna M. Hughes, as Senior Vice President, Human ... Vice President, Chief Compliance Officer. Both Ms. Hughes and ... Executive Officer, Fred Wilkinson . "We ... Impax team," said Fred Wilkinson , President and ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3
... on complex cases, facility called ,future of hospital care, ... announces the opening of the Hamon Tower, the largest expansion ... intensive care for the region,s most critically ill patients. , ... new clinical programs for ICU patients, Hamon Tower is designed ...
... IRVINE, Calif., Oct. 2 ISTA Pharmaceuticals, Inc. (Nasdaq: ... financial results after market close on November 3, 2009. In ... p.m. Eastern Time to discuss these results and provide a ... , Time: 5:00 p.m. Eastern Time , Conference call ...
Cached Medicine Technology:Hamon Tower Features Critical Care Advances, Potential for Reduced Costs 2
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... 2015 Each year, the Susan G. Komen ... and awareness for breast cancer. This year, Dr. Mark Deutsch ... as the entertainment sponsor for the 25th annual Susan G. ... at the Lenox Square Mall. , The Komen organization hopes ... raise $1.2 million. Perimeter Plastic Surgery has not only taken ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Getting ... to manage their health is critical to achieving the ... and reducing costs, but this will require a shift ... change also demands that health systems move beyond their ... who took part in the third live meeting of ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2
... children of a lesser God. The physical, mental, moral ... One stumbling handicap in the surgical treatment of such ... children. In many cases the anesthesia times ranged from ... placement to hemispherectomy. There is however light at ...
... In India Kidney Stones are not uncommon problem due to the ... up of Calcium, Oxalate and phosphates. The cause of stone disease ... water is a risk factor for stone disease. , ... is a tiny bacteria called Nano bacteria., ,These bacteria ...
... is often difficult to diagnose and many a times ... reaction (PCR) is emerging as a promising technique for ... of bacteria by facilitating rapid amplification of small amounts ... the Millennium International Urology Congress in India. Presence ...
... Transdermal hormone replacement therapy (HRT) does not ... postmenopausal women with existing ,coronary artery disease ... ,Atherosclerosis Study), researchers randomized 255 ,postmenopausal women ... receive either transdermal HRT--17-beta-estradiol ,with or without ...
... way for the survival of endangered animal species of the ... who engineered the feat has managed to clone cells from ... cow with the clone. , ,The scientific journal Cloning ... is expected to deliver the cloned Asian gaur sometime ...
... to have said that more than two-thirds of births in ... from a maternity clinic is suffering health problems. , ... 1992 to just 30 percent last year, said Olga Frolova, ... Science. She thinks that the decline is due to the ...
Cached Medicine News:
Microwell EIA for the detection of EPO (Erythropoietin)...
Microwell EIA for detection of Calcitonin...
... PREMIUM SURGICLIP II™ single ... Titanium Super Interlock™ clips., ... clip applier has application in ... to occlude vessels and other ...
... clip applier consists of an applier shaft with ... 20 titanium clips. , ,The clip applier ... tubular structure. As the handles of the applier ... the vessel or structure. As the handles are ...
Medicine Products: